HPA Axis Dysfunction: Causes, Symptoms, Diagnosis, and Treatment

What Is the HPA Axis and Why Does It Fail?

The hypothalamic-pituitary-adrenal axis is the body's primary stress-response circuit. The hypothalamus releases corticotropin-releasing hormone (CRH), which drives the anterior pituitary to secrete adrenocorticotropic hormone (ACTH), which in turn tells the adrenal cortex to produce cortisol. Cortisol then feeds back negatively to suppress both CRH and ACTH, completing the loop. When any node in that chain malfunctions, the entire system falls out of calibration.

Three broad failure modes exist. First, the adrenal glands themselves may be destroyed (primary insufficiency, or Addison's disease). Second, pituitary or hypothalamic disease may reduce ACTH drive (secondary or tertiary insufficiency). Third, a pituitary adenoma or ectopic tumor may produce ACTH in an autonomous, feedback-resistant manner, causing cortisol excess (Cushing's disease or Cushing's syndrome). Each failure mode requires a different diagnostic workup and an entirely different treatment strategy.

Chronic exogenous glucocorticoid use is now the single most common cause of HPA axis suppression globally. A 2017 analysis published in The Journal of Clinical Endocrinology and Metabolism estimated that 0.5 to 1% of the general population in high-income countries takes long-term oral glucocorticoids, and a significant fraction develops measurable secondary adrenal insufficiency as a result [1].

Primary Adrenal Insufficiency (Addison's Disease)

Addison's disease occurs when the adrenal cortex cannot produce adequate cortisol or aldosterone regardless of how much ACTH the pituitary secretes. Autoimmune destruction accounts for about 80 to 90% of primary adrenal insufficiency cases in developed countries [2].

What causes Addison's disease?

Autoimmune adrenalitis is the dominant cause. The adrenal cortex is attacked by antibodies targeting 21-hydroxylase, the enzyme that converts progesterone to cortisol precursors. Other causes include bilateral adrenal hemorrhage (Waterhouse-Friderichsen syndrome from meningococcemia), tuberculosis (still common in endemic regions), adrenal metastases, and congenital adrenal hyperplasia.

Loss of glucocorticoid secretion produces fatigue, weight loss, nausea, hypotension, and hyperpigmentation. That last sign is unique to primary insufficiency. When cortisol is absent, ACTH surges; ACTH shares a precursor (pro-opiomelanocortin, or POMC) with melanocyte-stimulating hormone, producing the characteristic bronze discoloration of skin creases, gingiva, and sun-exposed areas.

Diagnosing primary adrenal insufficiency

A morning serum cortisol below 3 mcg/dL essentially confirms the diagnosis; above 15 mcg/dL makes it very unlikely [3]. The Endocrine Society's 2016 Clinical Practice Guideline states: "We recommend the standard-dose (250 mcg) ACTH stimulation test as the preferred dynamic test for diagnosis of primary and secondary AI" [4]. A peak cortisol below 18 mcg/dL at 30 or 60 minutes post-injection is diagnostic.

Plasma ACTH distinguishes primary from secondary disease. In Addison's disease, ACTH typically exceeds 100 pg/mL (reference range 10, 60 pg/mL). Adrenal autoantibodies to 21-hydroxylase are positive in 80 to 90% of autoimmune cases and, when detected, obviate adrenal imaging in straightforward presentations [2].

Treating Addison's disease

Hydrocortisone 15 to 25 mg/day in two to three divided doses is the standard replacement. The Endocrine Society guideline recommends taking the largest dose on waking to mimic the physiological cortisol peak [4]. Fludrocortisone 0.05 to 0.2 mg once daily replaces aldosterone. Patients should wear a medical alert bracelet and carry injectable hydrocortisone 100 mg for emergencies.

Sick-day rules matter enormously. During a febrile illness, patients must double their hydrocortisone dose; before surgery requiring general anesthesia, a stress-dose of 50 to 100 mg hydrocortisone IV is standard. Without these precautions, adrenal crisis, characterized by vascular collapse and a case-fatality rate of approximately 6% per episode, can occur [5].

Secondary Adrenal Insufficiency

Secondary adrenal insufficiency differs from Addison's disease in one critical anatomical detail: the adrenals are intact, but the pituitary does not send enough ACTH to stimulate them. Because the adrenal glands are still functional, aldosterone secretion (which is regulated mainly by the renin-angiotensin system, not ACTH) is usually preserved, so hyperkalemia and hyperpigmentation are absent.

Causes of secondary adrenal insufficiency

Exogenous glucocorticoid use tops the list. When a patient takes prednisone, dexamethasone, or any synthetic glucocorticoid for more than three to four weeks, the hypothalamus and pituitary reduce CRH and ACTH output. Abrupt discontinuation of long-term steroids can precipitate an adrenal crisis before axis recovery occurs.

Pituitary tumors, pituitary surgery or radiation, traumatic brain injury, and infiltrative diseases such as sarcoidosis or hemochromatosis can all destroy corticotroph cells. Sheehan's syndrome, postpartum pituitary infarction from obstetric hemorrhage, causes combined anterior pituitary failure, including secondary adrenal insufficiency.

Testing and treatment

The 250 mcg ACTH stimulation test remains the recommended first-line test, though some centers prefer the insulin tolerance test for patients within six months of pituitary surgery because stimulated ACTH levels may still be transiently high while axis recovery is incomplete [4]. A peak cortisol below 18 mcg/dL confirms insufficiency.

Treatment is identical to Addison's disease in its glucocorticoid component: hydrocortisone 15 to 25 mg/day in divided doses. Mineralocorticoid replacement is not required. Recovery of endogenous axis function after glucocorticoid withdrawal may take six to twelve months, and serial morning cortisols or ACTH stimulation tests guide the taper schedule.

Cushing's Syndrome and Cushing's Disease

Cushing's syndrome describes the clinical state produced by prolonged exposure to excess glucocorticoids, from any source. Cushing's disease specifically refers to a pituitary adenoma secreting ACTH autonomously, and it accounts for roughly 70% of endogenous Cushing's syndrome cases [6].

Recognizing the clinical picture

Centripetal obesity, purple striae wider than 1 cm, proximal myopathy, facial plethora, easy bruising, and hypertension are the most discriminating features. The European Journal of Endocrinology's 2016 consensus notes that "no single clinical feature or biochemical test has sufficient sensitivity and specificity to diagnose Cushing's syndrome alone" [7]. A systematic approach is required.

Incidental detection is increasingly common. Adrenal incidentalomas are found in roughly 1 to 2% of abdominal CT scans performed for other indications, and about 10% of those harbor subclinical autonomous cortisol secretion [8].

Biochemical diagnosis of Cushing's syndrome

Three first-line screening tests are recommended by the Endocrine Society: the 1 mg overnight dexamethasone suppression test (DST), late-night salivary cortisol (LNSC), and 24-hour urine free cortisol (UFC). Two abnormal results from two different test types are generally required before pursuing a source [6].

The 1 mg overnight DST involves taking dexamethasone at 11 PM and measuring serum cortisol at 8 AM the next morning. Cortisol above 1.8 mcg/dL is abnormal with 95% sensitivity for Cushing's syndrome [6]. Late-night salivary cortisol exploits the fact that cortisol normally reaches its daily nadir at midnight; autonomous secretion blunts this trough. Two LNSC values above the laboratory's upper reference range (usually 0.13 mcg/dL in most assay systems) constitute a positive screen.

Once biochemical hypercortisolism is confirmed, ACTH measurement distinguishes ACTH-dependent from ACTH-independent disease. A plasma ACTH below 5 pg/mL suggests a cortisol-secreting adrenal tumor suppressing pituitary output. ACTH above 15, 20 pg/mL points to a pituitary adenoma or ectopic ACTH source.

Pituitary Cushing's disease: finding and treating the adenoma

Gadolinium-enhanced pituitary MRI identifies an adenoma in about 60% of confirmed Cushing's disease cases; the remaining 40% require inferior petrosal sinus sampling (IPSS) to confirm pituitary origin before surgery [7].

Transsphenoidal surgery by an experienced neurosurgeon produces remission in 65 to 90% of microadenoma cases. The Endocrine Society guideline states: "We recommend transsphenoidal surgery as first-line treatment for Cushing's disease" [6]. Post-operative cortisol below 2 mcg/dL within 72 hours predicts remission. Patients who fail surgery may proceed to repeat surgery, bilateral adrenalectomy, radiation, or pharmacotherapy with pasireotide, cabergoline, metyrapone, ketoconazole, or mifepristone.

A 2020 multicenter study (N=278) in the Journal of Clinical Endocrinology and Metabolism found that bilateral adrenalectomy achieved immediate control of hypercortisolism in 95% of Cushing's disease cases refractory to pituitary surgery, but 38% developed Nelson's syndrome (pituitary tumor progression) within five years [9].

Subclinical HPA Dysregulation: What the Evidence Actually Shows

The term "adrenal fatigue" appears in no peer-reviewed diagnostic classification. Neither ICD-11 nor DSM-5 recognizes it as a clinical entity. Patients with fatigue, salt cravings, and sleep disruption who do not meet biochemical criteria for adrenal insufficiency or Cushing's syndrome deserve a systematic search for other causes, not empirical glucocorticoid prescriptions.

A practical three-tier clinical framework helps clarify the distinction:

Tier 1: Biochemically confirmed HPA disease. Morning cortisol below 3 mcg/dL or ACTH stimulation peak below 18 mcg/dL confirms insufficiency. Morning cortisol above 1.8 mcg/dL after 1 mg DST, with elevated UFC and LNSC, confirms Cushing's. These patients need formal endocrinology management.

Tier 2: Subclinical autonomous cortisol secretion (SACS). This is a real and growing category. Patients with adrenal incidentalomas who fail to suppress cortisol below 1.8 mcg/dL on 1 mg DST but lack overt Cushing's features may have SACS. The 2023 European Society of Endocrinology guideline recommends screening all incidentaloma patients for this condition, given its association with hypertension, type 2 diabetes, and vertebral fractures [8].

Tier 3: Normal biochemistry with stress-related symptoms. These patients may have genuine dysregulation of sleep architecture, autonomic tone, or inflammatory signaling, but their cortisol production is intact. Glucocorticoid supplementation in this group carries real harm: iatrogenic HPA suppression, weight gain, and glucose intolerance.

Clinicians using this framework can avoid both under-treating true insufficiency and prescribing unnecessary steroids. The framework does not replace full biochemical evaluation; it structures the sequence of that evaluation.

HPA Axis Dysfunction in Special Populations

Post-COVID and critical illness

Prolonged critical illness suppresses the HPA axis through inflammatory cytokine interference with CRH and ACTH secretion. A 2021 study in Critical Care Medicine found that 25% of patients surviving ICU stays of more than 14 days had ACTH stimulation peak cortisol below 18 mcg/dL at hospital discharge [10]. Empirical stress-dose hydrocortisone during septic shock, per the 2021 Surviving Sepsis Campaign, is recommended when norepinephrine dose exceeds 0.25 mcg/kg/min for at least four hours.

Post-COVID fatigue has prompted renewed interest in HPA recovery trajectories. A 2022 observational cohort (N=199) published in The Lancet Regional Health Europe found that 12% of long-COVID patients had morning cortisol levels at least 30% lower than age-matched controls at six months post-infection, though most remained above diagnostic cut-offs for insufficiency [11]. This finding is preliminary and does not support empirical cortisol supplementation in long-COVID without formal testing.

Pregnancy and the HPA axis

Cortisol-binding globulin rises sharply in pregnancy, elevating total cortisol while free cortisol increases only modestly. Standard cortisol reference ranges are not valid in pregnant patients. The ACTH stimulation test remains interpretable, but the diagnostic cut-off for peak cortisol may need to be raised to 22 to 25 mcg/dL in the third trimester based on normative data published by Lindsay and Nieman in 2005 [12]. Cushing's syndrome in pregnancy is rare (fewer than 200 reported cases) but carries significant maternal and fetal risk, with 30 to 40% rates of preterm delivery and gestational diabetes [12].

Pediatric HPA axis dysfunction

Congenital adrenal hyperplasia (CAH) from 21-hydroxylase deficiency is the most common cause of primary adrenal insufficiency in children, with an incidence of roughly 1 in 15,000 live births in the United States [13]. Newborn screening programs in all 50 US states now measure 17-hydroxyprogesterone to catch classic salt-wasting CAH. Treatment uses hydrocortisone 10 to 15 mg/m2/day in three divided doses to suppress excess androgen production while replacing cortisol.

Diagnostic Workup: A Step-by-Step Approach

Clinicians evaluating a patient for HPA axis dysfunction should sequence tests in a defined order to avoid false positives and unnecessary procedures.

Step 1: Clinical probability assessment. Document all current and recent glucocorticoid use (oral, inhaled, topical, and intra-articular). Inhaled fluticasone at doses above 500 mcg/day and topical clobetasol applied to large body surface areas can suppress the axis measurably [1].

Step 2: Morning serum cortisol. Draw between 7 and 9 AM. Below 3 mcg/dL is likely insufficient; above 15 mcg/dL makes insufficiency very unlikely; 3 to 15 mcg/dL is indeterminate and requires dynamic testing [4].

Step 3: ACTH stimulation test. Standard dose: 250 mcg cosyntropin IV or IM. Measure cortisol at 0, 30, and 60 minutes. Peak below 18 mcg/dL confirms adrenal insufficiency.

Step 4: Plasma ACTH. Drawn simultaneously with a low baseline cortisol sample. High ACTH (above 100 pg/mL) confirms primary disease; normal or low ACTH with low cortisol points to secondary or tertiary origin.

Step 5: If Cushing's is suspected. Order two of the three recommended screening tests (1 mg overnight DST, LNSC x2, 24-hour UFC). Do not interpret results during acute illness, depression, alcoholism, or high-dose biotin supplementation, all of which cause false positives.

Step 6: Source localization. Confirmed endogenous hypercortisolism requires ACTH measurement, then dedicated pituitary MRI if ACTH-dependent, or adrenal CT/MRI if ACTH-independent.

Monitoring and Long-Term Management

Patients on long-term hydrocortisone replacement require periodic reassessment. Annual bone density by DEXA is recommended given the association between even physiological glucocorticoid doses and bone loss over years. Blood pressure and fasting glucose should be checked at each visit.

Cortisol day curves, measuring serum cortisol at 0, 30, 60, and 120 minutes after the morning hydrocortisone dose, help assess whether peak levels are adequate (target 20 to 30 mcg/dL at 60 minutes) and trough levels are not excessive [4]. Some centers use continuous glucose monitoring as a surrogate for glucocorticoid overexposure, since nocturnal hyperglycemia tracks closely with excess cortisol timing.

For Cushing's syndrome patients in remission after surgery, recovery of the contralateral adrenal suppressed by chronic hypercortisolism takes months. These patients are effectively in secondary adrenal insufficiency during the recovery phase and need temporary hydrocortisone replacement until a normal ACTH stimulation test confirms axis recovery. The median time to axis recovery in a retrospective series of 78 post-surgical Cushing's disease patients was 14.5 months [9].